Samsung Biologics has signed an agreement with Texas-based biotech company Enzolytics for developing and manufacturing monoclonal antibody therapy for Covid-19.

Under the accord, Samsung Biologics will provide an end-to-end service to develop cell lines, manufacture clinical trial material, and apply study plans of its partner's monoclonal antibody candidates for Covid-19 and HIV.

The two companies also agreed to discuss further Enzolytics' pipeline of monoclonal antibodies for other diseases.

Enzolytics has developed antibody therapeutics based on artificial intelligence (AI) platform that can respond to mutated viruses by targeting immutable sites that do not change within the viruses.

Samsung Biologics plans to support the development of Enzolytics' cell line and from facilities in San Francisco and make the clinical trial materials in plants placed in Incheon.

"With our world's most competitive end-to-end CDMO service, we believe Enzolytics will successfully achieve its goals," Samsung Biologics CEO John Rim said. "We will speed up the development of new drugs with quality service and expertise to quickly supply therapeutics to patients around the world."

Enzolytics COO Gaurav Chandra also said, "We have chosen Samsung Biologics because of the company's experience and expertise in developing, producing, and manufacturing monoclonal antibodies."

Chandra added that Enzolytics would conduct successful clinical trials and shorten the development period to offer much-needed treatment for patients.